for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Regeneron Pharmaceuticals Inc

REGN.O

現在値

537.64USD

変化

1.63(+0.30%)

出来高

220,585

本日のレンジ

532.12

 - 

539.64

52週レンジ

441.00

 - 

664.64

∙ 約20分前の相場を表示しています。

適時開示

FDA Authorizes Lower Dose Of Regen-Cov Antibody Cocktail To Treat COVID-19

June 4 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::FDA AUTHORIZES LOWER 1,200 MG INTRAVENOUS AND SUBCUTANEOUS DOSE OF REGEN-COV™ (CASIRIVIMAB AND IMDEVIMAB) ANTIBODY COCKTAIL TO TREAT PATIENTS WITH COVID-19.REGENERON - EXPECTS TO SUBMIT A FULL BIOLOGICS LICENSE APPLICATION FOR REGEN-COV IN NON-HOSPITALIZED OUTPATIENTS WITH COVID-19 LATER THIS SUMMER.REGENERON - U.S. GOVERNMENT TO BUY ALL REGEN-COV DOSES DELIVERED BY JUNE 30, 2021, MAY ACCEPT ADDITIONAL DOSES THROUGH SEPTEMBER 30, 2021 AT ITS DISCRETION.REGENERON - U.S. GOVERNMENT MAY ACCEPT ADDITIONAL DOSES THROUGH SEPTEMBER 30, 2021 AT ITS DISCRETION, UP TO A MAXIMUM AMOUNT OF 1.25 MILLION DOSES.REGENERON PHARMACEUTICALS INC - EXPECTS TO DELIVER AT LEAST 1 MILLION REGEN-COV DOSES TO U.S. GOVERNMENT IN Q2..

Libtayo (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers

May 24 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::REGENERON- EMA COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ADOPTED POSITIVE OPINIONS FOR LIBTAYO (CEMIPLIMAB) AS MONOTHERAPY IN 2 ADVANCED CANCERS.CHMP HAS NOW ISSUED THREE POSITIVE OPINIONS FOR LIBTAYO IN ADVANCED CANCERS.REGENERON-LIBTAYO APPROVAL RECOMMENDED IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA WHO'VE PROGRESSED OR ARE INTOLERANT TO HEDGEHOGPATHWAY INHIBITOR.

Regeneron Reports Q1 Non-Gaap Earnings Per Share $9.89

May 6 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::REGENERON REPORTS FIRST QUARTER 2021 FINANCIAL AND OPERATING RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $9.89.Q1 GAAP EARNINGS PER SHARE $10.09.Q1 2021 EYLEA U.S. NET SALES INCREASED 15% TO $1.35 BILLION VERSUS Q1 2020.Q1 2021 REVENUES INCREASED 38% TO $2.53 BILLION VERSUS Q1 2020.Q1 EARNINGS PER SHARE VIEW $9.00, REVENUE VIEW $2.55 BILLION -- REFINITIV IBES DATA.SEES 2021 CAPITAL EXPENDITURES OF $585 MILLION–$650 MILLION.QTRLY REGEN-COV SALES $262 MILLION.REGENERON - ANTICIPATES BEING ABLE TO PROVIDE AT LEAST 1 MILLION DOSES OF REGEN-COV BY JUNE 30, 2021 IF EUA IS UPDATED TO LOWER 1,200 MG DOSE.QTRLY REGEN-COV NET PRODUCT SALES $262 MILLION.

Regeneron Pharmaceuticals Says CEO Leonard S. Schleifer’S FY 2020 Total Compensation Was $135.4 Million Including $130.0 Million In Stock Awards - SEC Filing

April 23 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::REGENERON PHARMACEUTICALS SAYS CEO LEONARD S. SCHLEIFER’S FY 2020 TOTAL COMPENSATION WAS $135.4 MILLION INCLUDING $130.0 MILLION IN STOCK AWARDS - SEC FILING.REGENERON PHARMACEUTICALS SAYS CEO LEONARD S. SCHLEIFER’S FY 2019 TOTAL COMPENSATION WAS $21.5 MILLION.REGENERON PHARMACEUTICALS - CHIEF SCIENTIFIC OFFICER GEORGE D. YANCOPOULOS’S FY 2020 TOTAL COMPENSATION WAS $134.4 MILLION INCLUDING $130.0 MILLION IN STOCK AWARDS.REGENERON PHARMACEUTICALS - CHIEF SCIENTIFIC OFFICER GEORGE D. YANCOPOULOS’S FY 2019 TOTAL COMPENSATION WAS $20.7 MILLION.REGENERON PHARMACEUTICALS SAYS FOR 2020 CEO PAY RATIO WAS 933 TO 1..

Regeneron Pharmaceuticals Says NIH-sponsored Trial Finds EYLEA Injection Reduced Vision-Threatening Complications By 68% After 2 Years In Diabetic Retinopathy Patients

March 30 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::NIH-SPONSORED TRIAL FINDS EYLEA® (AFLIBERCEPT) INJECTION REDUCED VISION-THREATENING COMPLICATIONS BY 68% AFTER TWO YEARS IN DIABETIC RETINOPATHY PATIENTS.REGENERON TO DISCUSS 16-WEEK DOSING INTERVAL WITH U.S. FDA.REGENERO- PROTOCOL W TRIAL DATA CONFIRM RESULTS FROM PANORAMA TRIAL SHOWING EYLEA SIGNIFICANTLY REDUCED VISION-THREATENING COMPLICATIONS.NO NEW SAFETY SIGNALS WERE IDENTIFIED IN PROTOCOL W, CONSISTENT WITH KNOWN SAFETY PROFILE OF EYLEA.REGENERON PHARMACEUTICALS- PROTOCOL W TRIAL DATA CONFIRM RESULTS FROM PANORAMA TRIAL SHOWING EYLEA IMPROVED ANATOMIC MEASURES OF DIABETIC RETINOPATHY.REGENERON PHARMACEUTICALS - TWO DIABETIC RETINOPATHY TRIALS HAVE NOW SHOWN BENEFIT OF EYLEA EVERY 16 WEEKS FOLLOWING AN INITIAL DOSING PERIOD.

Regeneron Says Phase 3 Trial Shows REGEN-COV Antibody Cocktail Reduced Hospitalization Or Death By 70% In Non-Hospitalized COVID-19 Patients

March 23 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::PHASE 3 TRIAL SHOWS REGEN-COV™ (CASIRIVIMAB WITH IMDEVIMAB) ANTIBODY COCKTAIL REDUCED HOSPITALIZATION OR DEATH BY 70% IN NON-HOSPITALIZED COVID-19 PATIENTS.REGEN-COV ALSO SIGNIFICANTLY SHORTENED DURATION OF SYMPTOMS BY 4 DAYS.ALL DOSES (8,000 MG, 2,400 MG AND 1,200 MG) HAD SIMILAR EFFICACY ACROSS ALL ENDPOINTS.TO SHARE NEW DATA WITH REGULATORY AUTHORITIES IMMEDIATELY AND REQUEST THAT A LOWER 1,200 MG DOSE BE ADDED TO EUA.ANTICIPATES RECORDING ABOUT $260 MILLION IN REGEN-COV U.S. NET PRODUCT SALES TO U.S. GOVERNMENT IN Q1 OF 2021.REGEN-COV SALES UNDER SECOND U.S. GOVERNMENT AGREEMENT NOW EXPECTED TO BEGIN IN Q2 OF 2021.

Sanofi's Phase 3 Trial Of Libtayo (Cemiplimab) Stopped Early For Positive Result On Overall Survival

March 15 (Reuters) - SANOFI SA <SASY.PA>::PHASE 3 TRIAL OF LIBTAYO® (CEMIPLIMAB) MONOTHERAPY IN ADVANCED CERVICAL CANCER STOPPED EARLY FOR POSITIVE RESULT ON OVERALL SURVIVAL.FOURTH CANCER TYPE WHERE LIBTAYO HAS POSITIVE PIVOTAL DATA; REGULATORY SUBMISSIONS PLANNED IN 2021.THIS TRIAL WILL BE STOPPED EARLY BASED ON A UNANIMOUS RECOMMENDATION BY INDEPENDENT DATA MONITORING COMMITTEE (IDMC), AND DATA WILL FORM BASIS OF REGULATORY SUBMISSIONS IN 2021.DATA CONTRIBUTE TO GROWING EVIDENCE DEMONSTRATING SIGNIFICANT POTENTIAL OF LIBTAYO TO TREAT A SPECTRUM OF DIFFICULT-TO-TREAT CANCERS.

Regeneron Pharmaceuticals Says FDA Accepts Dupixent (Dupilumab) For Review In Children With Moderate-To-Severe Asthma

March 4 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::FDA ACCEPTS DUPIXENT® (DUPILUMAB) FOR REVIEW IN CHILDREN WITH MODERATE-TO-SEVERE ASTHMA.REGENERON PHARMACEUTICALS- TARGET ACTION DATE FOR FDA DECISION IS OCTOBER 21, 2021.REGENERON PHARMACEUTICALS- EU REGULATORY SUBMISSION FOR CHILDREN AGED 6 TO 11 YEARS WITH ASTHMA IS PLANNED FOR Q1 2021.

EMA Issues Advice On Regeneron's Antibody Cocktail For Certain COVID-19 Patients

Feb 26 (Reuters) - Regeneron Pharmaceuticals Inc <REGN.O>::EMA ISSUES ADVICE ON REGENERON'S ANTIBODY COCKTAIL (CASIRIVIMAB WITH IMDEVIMAB) FOR CERTAIN COVID-19 PATIENTS.REGENERON PHARMACEUTICALS - EMA'S CHMP HAS ISSUED A POSITIVE OPINION FOR CO'S INVESTIGATIONAL COVID-19 ANTIBODY COCKTAIL.REGENERON PHARMA - CHMP RECOMMENDS CO'S ANTIBODY COCKTAIL, CAN BE USED TO TREAT CONFIRMED COVID-19 IN PATIENTS WHO DON'T REQUIRE SUPPLEMENTAL OXYGEN.REGENERON PHARMA - CHMP RECOMMENDS CO'S ANTIBODY COCKTAIL CAN BE USED TO TREAT PATIENTS WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE COVID-19.REGENERON PHARMACEUTICALS - COLLABORATING WITH ROCHE TO INCREASE GLOBAL SUPPLY OF ANTIBODY COCKTAIL.

EMA Issues Advice On Use Of REGN-COV2 Antibody Combination

Feb 26 (Reuters) - EMA: :EMA SAYS ISSUES ADVICE ON USE OF REGN-COV2 ANTIBODY COMBINATION (CASIRIVIMAB / IMDEVIMAB).EMA SAYS THE MEDICINE IS GIVEN BY INFUSION (DRIP) INTO A VEIN AND THE PROPOSED CONDITIONS OF USE ARE AVAILABLE.EMA SAYS CONCLUDED COMBINATION ALSO KNOWN AS REGN-COV2 CAN BE USED FOR TREATMENT OF CONFIRMED COVID-19 IN PATIENTS WHO DO NOT REQUIRE SUPPLEMENTAL OXYGEN.EMA SAYS IN PARALLEL, A ROLLING REVIEW OF THE COMBINATION OF ANTIBODIES CASIRIVIMAB AND IMDEVIMAB, WHICH STARTED ON 1ST FEBRUARY, IS CURRENTLY ONGOING.EMA SAYS CONCLUDED COMBINATION ALSO KNOWN AS REGN-COV2 CAN BE USED FOR TREATMENT OF CONFIRMED COVID-19 IN PATIENTS AT HIGH RISK OF PROGRESSING TO SEVERE COVID-19.EMA, ON REGN-COV2, SAYS ON SAFETY, MOST SIDE EFFECTS REPORTED MILD OR MODERATE, BUT REACTIONS RELATED TO INFUSION HAVE BEEN SEEN, SHOULD BE MONITORED.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up